| # | Title | Journal | Year | Citations |
|---|
| 1 | Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial | Lancet Oncology, The | 2021 | 260 |
| 2 | Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets | Cell Metabolism | 2021 | 211 |
| 3 | A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients | Annals of Oncology | 2008 | 167 |
| 4 | Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19) | European Journal of Cancer | 2020 | 122 |
| 5 | Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin | Annals of Oncology | 2010 | 111 |
| 6 | Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies | Blood Cancer Journal | 2021 | 106 |
| 7 | Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV | Annals of Oncology | 2016 | 105 |
| 8 | Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study | Journal of Clinical Oncology | 2023 | 98 |
| 9 | Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients | Annals of Oncology | 2021 | 68 |
| 10 | Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors | Journal of Nuclear Medicine | 2017 | 64 |
| 11 | Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review | Cancer Medicine | 2014 | 61 |
| 12 | Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer | Annals of Oncology | 2008 | 55 |
| 13 | PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer | European Journal of Cancer | 2017 | 48 |
| 14 | RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study | | 2020 | 43 |
| 15 | Greatwall promotes cell transformation by hyperactivating AKT in human malignancies | ELife | 2015 | 43 |
| 16 | Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): The GERCOR NEONIPIGA phase II study. | Journal of Clinical Oncology | 2022 | 39 |
| 17 | High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers | Annals of Oncology | 2021 | 38 |
| 18 | The use of estramustine phosphate in the modern management of advanced prostate cancer | BJU International | 2011 | 37 |
| 19 | New cancer cases at the time of SARS-Cov2 pandemic and related public health policies: A persistent and concerning decrease long after the end of the national lockdown | European Journal of Cancer | 2021 | 37 |
| 20 | Multicenter evaluation of breast cancer patients’ satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic | British Journal of Cancer | 2021 | 37 |
| 21 | Lymphovascular invasion has a significant prognostic impact in patients with early breast cancer, results from a large, national, multicenter, retrospective cohort study | ESMO Open | 2021 | 36 |
| 22 | Enhanced recovery after surgery program in Gynaecologic Oncological surgery in a minimally invasive techniques expert center | BMC Surgery | 2017 | 32 |
| 23 | Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data | Critical Reviews in Oncology/Hematology | 2019 | 30 |
| 24 | Biomarker Discovery, Development, and Implementation in France: A Report from the French National Cancer Institute and Cooperative Groups | Clinical Cancer Research | 2012 | 27 |
| 25 | Immune checkpoint inhibitors in people living with HIV: what about anti-HIV effects? | Aids | 2020 | 25 |
| 26 | Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study | European Journal of Cancer | 2017 | 24 |
| 27 | Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial | Genome Medicine | 2021 | 24 |
| 28 | Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers | European Journal of Cancer | 2022 | 24 |
| 29 | Patient-reported tolerability of adverse events in phase 1 trials | ESMO Open | 2017 | 20 |
| 30 | Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit | Breast Cancer Research and Treatment | 2019 | 20 |
| 31 | Adjuvant chemotherapy for small, lymph node–negative, triple‐negative breast cancer: A single‐center study and a meta‐analysis of the published literature | Cancer | 2020 | 20 |
| 32 | RUBY: A phase II study testing rucaparib in germline (g) BRCA wild-type patients presenting metastatic breast cancer (mBC) with homologous recombination deficiency (HRD). | Journal of Clinical Oncology | 2019 | 20 |
| 33 | Enhancing Abiraterone Acetate Efficacy in Androgen Receptor–positive Triple-negative Breast Cancer: Chk1 as a Potential Target | Clinical Cancer Research | 2019 | 19 |
| 34 | Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer | Oncotarget | 2018 | 17 |
| 35 | TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT | EMBO Molecular Medicine | 2022 | 17 |
| 36 | Tumor control by human cytomegalovirus in a murine model of hepatocellular carcinoma | Molecular Therapy - Oncolytics | 2016 | 16 |
| 37 | Rapalog combined with CCR4 antagonist improves anticancer vaccines efficacy | International Journal of Cancer | 2018 | 16 |
| 38 | Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact | Breast Cancer Research and Treatment | 2019 | 16 |
| 39 | A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: Results of GETUG 13. | Journal of Clinical Oncology | 2013 | 16 |
| 40 | A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen | BMC Cancer | 2017 | 14 |
| 41 | Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors | Lung Cancer | 2021 | 14 |
| 42 | Lack of prognostic impact of sentinel node micro-metastases in endocrine receptor-positive early breast cancer: results from a large multicenter cohort☆ | ESMO Open | 2021 | 13 |
| 43 | Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients | Annals of Oncology | 2022 | 12 |
| 44 | PARP inhibitors and radiation potentiate liver cell death in vitro. Do hepatocellular carcinomas have an achilles’ heel? | Clinics and Research in Hepatology and Gastroenterology | 2021 | 11 |
| 45 | Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER) | European Journal of Cancer | 2021 | 11 |
| 46 | Enhanced recovery after surgery program in older patients undergoing gynaecologic oncological surgery is feasible and safe | Gynecologic Oncology | 2018 | 10 |
| 47 | Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial | BMC Cancer | 2021 | 9 |
| 48 | Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: Real‐world data from a multicentric European cohort | International Journal of Cancer | 2022 | 9 |
| 49 | Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy | Human Gene Therapy | 2018 | 8 |
| 50 | Serum glial fibrillary acidic protein is a predictor of brain metastases in patients with metastatic breast cancer | International Journal of Cancer | 2021 | 8 |
